| abstract |
The invention provides a fluorescence-radioactivity combined in-vitro targeted screening method, which comprises the following steps: combining a drug to be detected on a solid phase carrier, and adding a target molecule marked by a radionuclide and the same target molecule marked by a fluorescent probe; after competitive combination is formed, fluorescent and radioactive signals are synchronously detected, two groups of data results which can be mutually verified are obtained and are used for more accurately analyzing the combination capacity of the drug and the target molecule, and therefore targeted drug screening is achieved. The method can realize simultaneous detection of the binding fluorescence and radioactive signal intensity of a plurality of drugs to be detected in a single test, and quickly and efficiently screen out the drugs with high specific binding capacity to target molecules. The method can effectively reduce the probability of false positive, and has the characteristics of high flux, high accuracy, simple operation and the like. The antibody drug specifically binding with the target molecule can be rapidly screened out, and can be developed into a pre-target antibody for the indication of expanding the target radiopharmaceutical in radioactive targeting therapy. |